Major Depressive Disorder (MDD) - Drug Pipeline Landscape, 2023

Major Depressive Disorder (MDD) - Drug Pipeline Landscape, 2023

Major Depressive Disorder (MDD) also known as clinical depression, is a severe mood disorder which causes persistent or extended periods of depressed or low mood, for more than 2 weeks and a loss of interest in activities thus affecting the mood and ability to function in daily life.

The most common causes of Major Depressive Disorder include genetics, trauma, isolation, significant loss, chemical and hormonal imbalances, abnormal brain chemical levels, comorbid medical illness, medicinal side effects.

Symptoms include sleep disturbances, stress, lack of energy, changes in appetite, unintentional weight loss or gain, poor concentrating, persistently low or depressed mood, anhedonia or decreased interest in pleasurable activities, feelings of guilt or worthlessness, psychomotor retardation or agitation or suicidal thoughts.

Doctors will use a questionnaire to diagnose Major Depressive Disorder and evaluate symptoms as defined by the Diagnostic and Statistical Manual of Mental Disorders.

The most common treatments for Major Depressive Disorder are antidepressants, mood stabilizers, lifestyle changes, psychotherapy, cognitive behavioral therapy, or a combination of strategies.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Major Depressive Disorder (MDD) treatment such as Desvenlafaxine Succinate, Zuranolone, Aticaprant, Seltorexant, REL-1017 and others. Key players involved in the development of therapies to treat major depressive disorder are CSPC ZhongQi Pharmaceutical Technology Co., Ltd, Sage Therapeutics, Johnson & Johnson, Gilead Sciences, Relmada Therapeutics, Inc and others. Two drugs are under late-stage Pre-Registration, five drugs are under Phase III clinical trials, twenty-seven drugs are in Phase II clinical trials and some other drugs are under Phase I, IND/CTA Filed, Preclinical and Discovery stages of development.

In December 2022, Sage Therapeutics announced completion of rolling submission of New Drug Application for Zuranolone in the treatment of Major Depressive Disorder.

In December 2022, Relmada Therapeutics announced top-line results from Phase 3 RELIANCE I study (REL-1017-301), evaluating REL-1017 as an adjunctive treatment for Major Depressive Disorder (MDD).

Report Highlights

Global Insight Service's, Major Depressive Disorder (MDD) - Drug Pipeline Landscape, 2023 report provides an overview of the Major Depressive Disorder (MDD) pipeline drugs. This report covers detailed insights on Major Depressive Disorder (MDD) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Major Depressive Disorder (MDD) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.